Stockreport

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc.  (VERU) 
Last veru inc. earnings: 2/12 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: verupharma.com/investors
PDF -- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity o [Read more]